Home Tags PermaLink

Tag: PermaLink

Glythera and Cancer Research UK Collaborate in the Development of “Next-Gen”...

Peter Hofland
Cancer Research UK and Glythera, a company developing the "next-gen" antibody-drug conjugates or ADCs have agreed that Glythera receives exclusive, worldwide rights, to the...

Glythera Wins Grant to Develops Portfolio of PermaLink®-based ADCs

Peter Hofland
Glythera, a UK-based company has won a UK £ 1 million (US $ 1,12 million) Innovate UK grant to fund a new project to...

Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs

Peter Hofland
Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...

DOWNLOAD

ADC Review, Journal of Antibody-drug Conjugates
MADE POSSIBLE BY:
ADCBIO
Lonza
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policy makers.

News

Peer Review Articles

© 2013-2019 Sunvalley Communication, LLC. All Rights Reserved.